Mature platform technology for diagnostic, predictive, and prognostic tests in blood. Blood-based companion diagnostics and monitoring.
USB develops and intends to market biomarkers and blood-based diagnostic (Dx) tests for cancer and neurodegenerative diseases (e.g. multiple sclerosis). The Dx market grows due to aging populations, and healthcare costs. Matching of drugs to patients (companion Dx) and patient monitoring (personalized medicine) require tests. Customers are individuals, pharma and molecular Dx companies, and medical groups.